Product image of Milrinon Stragen (Milrinone) supplied by GNH India

Milrinon Stragen

Active Ingredient:
Milrinone
Origin:
EU

Milrinon Stragen (Milrinone)

Milrinone, the active ingredient in Milrinon Stragen, is a phosphodiesterase‑3 inhibitor presented as an injectable solution for intravenous use. It is employed to improve cardiac contractility and reduce vascular resistance in patients with acute decompensated heart failure or cardiogenic shock.

GNH India supplies Milrinon Stragen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide. The company adheres to stringent quality standards and provides reliable logistics for critical care medicines across global markets. Clients benefit from transparent pricing, regulatory support, and timely delivery.

Manufacturer / TM Owner

Stragen Nordic A/S

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Milrinone is used as an inotropic agent in conditions where cardiac output is compromised.

  • Acute decompensated heart failure: enhances myocardial contractility to improve systemic perfusion.
  • Cardiogenic shock: provides rapid inotropic support to maintain blood pressure and organ perfusion.
  • Post‑cardiac surgery low‑output syndrome: stabilizes hemodynamics during recovery.

How It Works

  • Milrinone selectively inhibits the enzyme phosphodiesterase‑3 in cardiac and vascular smooth‑muscle cells. Inhibition prevents the breakdown of cyclic adenosine monophosphate (cAMP), leading to increased intracellular cAMP levels. Elevated cAMP enhances calcium influx during systole, producing a positive inotropic effect, while simultaneously causing vasodilation through reduced calcium‑mediated smooth‑muscle contraction, thereby decreasing systemic vascular resistance.

Side Effects

Milrinone may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

  • Hypotension: drop in blood pressure, especially after rapid infusion.
  • Headache: mild to moderate intensity.
  • Nausea: occasional gastrointestinal upset.
  • Tachycardia: increased heart rate.

Serious or Rare Side Effects

  • Life‑threatening arrhythmias: ventricular tachycardia or fibrillation.
  • Severe hypotension: refractory low blood pressure.
  • Myocardial ischemia: chest pain due to reduced coronary perfusion.

Precautions & Warnings

When using Milrinone, clinicians should observe several safety considerations to minimize risk.

  • Monitor blood pressure: watch for hypotension during and after infusion.
  • Observe cardiac rhythm: detect arrhythmias promptly.
  • Adjust dose in renal impairment: reduced clearance may increase exposure.
  • Use with caution in severe hypotension: may exacerbate low pressure.
  • Contraindicate in known hypersensitivity: avoid in patients with allergy to milrinone or formulation components.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Avoid Interactions

Milrinone can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

  • Concurrent PDE‑3 inhibitors: additive inotropic effect may cause severe hypotension.
  • Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): increase milrinone plasma levels, raising toxicity risk.
  • Nitrates: combined vasodilatory action can lead to profound hypotension.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may blunt the inotropic response, requiring dose adjustments.
  • Diuretics: synergistic effect on blood pressure, necessitating close monitoring.
  • Calcium channel blockers: potential for altered vascular tone and cardiac effects.

Frequently Asked Questions

Milrinon Stragen contains milrinone, an intravenous inotropic agent used to increase cardiac contractility and reduce vascular resistance in patients with acute decompensated heart failure or cardiogenic shock, helping to restore adequate tissue perfusion.

Milrinone blocks phosphodiesterase‑3, which raises intracellular cyclic AMP levels in heart and vascular smooth‑muscle cells. The higher cAMP enhances calcium entry during heart muscle contraction, producing a stronger heartbeat, while also causing vasodilation that lowers systemic vascular resistance.

The specific dose of milrinone is determined by the prescribing clinician based on the patient’s clinical status, weight, renal function, and response to therapy. Dosing is individualized and administered under continuous medical supervision.

Safety data for milrinone in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Milrinone is a phosphodiesterase‑3 inhibitor, offering both positive inotropic and vasodilatory effects, whereas agents such as dopamine or dobutamine primarily increase contractility with less vasodilation. This dual action can be advantageous in low‑output states but may also increase the risk of hypotension.

Milrinon Stragen must be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze the product, and avoid shaking the vial. Follow standard aseptic techniques when preparing the solution for intravenous infusion.

Milrinon Stragen is supplied as an injectable solution for intravenous infusion. It is typically given as a loading dose followed by a continuous infusion, administered by qualified healthcare personnel in a monitored setting such as an intensive care unit.

The most serious risks include life‑threatening arrhythmias (ventricular tachycardia or fibrillation), severe hypotension that does not respond to standard measures, and myocardial ischemia. Continuous cardiac and hemodynamic monitoring is essential during therapy.

Milrinone is contraindicated in patients with known hypersensitivity to the drug or its excipients, and it should be avoided in individuals with severe uncontrolled hypotension or those who have recently received other phosphodiesterase‑3 inhibitors.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Milrinone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT